pretickt

Is TMO a good stock to buy?

Thermo Fisher Scientific Inc. · end-of-day data as of Nov 13, 2026

Thermo Fisher
TMO · $259B
$700.22+0.1%
Nov 13, 2026 · close
$600$650$700SepOctNov9:3016:003 months +19.0%Nov 13 · close
▲ 3
  • ConsensusBuy · 27
  • MAs4 of 4
  • Sector▲ +15.9%
Neutral
  • Earnings in83d
  • P/E36.9x
  • RSI54
  • Support-3.3%
  • Resistance+0.4%
  • Off 52w high-3.8%
  • Volume0.8x
  • Bollingerupper half
  • News1.00
  • FCF yield+2.9%
  • PT$706.70 +0.9%
  • Trendsideways
  • 52w range$435–$728
  • ATR+2.9%
  • Off ATH-3.8%
▼ 4
  • P/E vs own+21.2%
  • P/E vs sector+14.6%
  • Insiders-$24.29M
  • MACD-0.81

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Thermo Fisher a good stock to buy?

Thermo Fisher is strong on 3 of the 5 questions about the business; weak on demand and advantage. The price is high: 36.9 times its earnings, above its 3-year median of 32.1 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand shrinking
  2. Advantage easy to copy
  3. Economics profits growing
  4. Execution delivers
  5. Fragility sturdy
  6. Price expensive
DemandDo people want more of what it sells?shrinking

TMO sales growth revenue growth

0%a year, for the last 3 years

Thermo Fisher's sales fell 0% a year for 3 years, to $44.55B in fiscal 2025.

TMO analysts' forecast revenue estimates

+8%the sales they expect next fiscal year, on the last

Analysts expect Thermo Fisher's sales to grow 8% to $48B in fiscal 2026 (19 analysts).

TMO competitors

pretickt analysis+8%its sales in 12 months, on a year before

Thermo Fisher's sales grew 8% in the 12 months to Sep 26, 2026, faster than Danaher (+6%), slower than Natera (+37%), Idexx Laboratories (+12%) and Agilent (+9%).

TMO sales by business revenue by segment

42%of its sales from Consumables

Consumables brought Thermo Fisher 42% of its sales in fiscal 2025; Service 42%.

Advantage moatIs it hard to copy?easy to copy

TMO margin on each sale gross margin

41%left after making the product

Thermo Fisher kept 41% of each sale after making the product in the 12 months to Sep 26, 2026; its competitors' median is 61%.

EconomicsDoes it make good money?profits growing

TMO cash generated free cash flow

$7.6Bcash left after investing, last 12 months

Thermo Fisher generated $7.6B of free cash flow in the 12 months to Sep 26, 2026, about as much as its reported profit.

TMO profit per share

+7%in its last fiscal year

Thermo Fisher's earnings per share grew 7% in fiscal 2025, to $17.74.

ExecutionDoes it deliver what it promises?delivers

TMO earnings vs estimates

8 of 8quarters above the analysts' estimate

Thermo Fisher beat the analysts' profit estimate in each of its last 8 quarters, the latest on Oct 21, 2026.

TMO insider selling

-$130Msold, net, by its executives in 12 months

Thermo Fisher's executives and directors sold a net $130M of shares in the 12 months to Nov 13, 2026; none bought.

TMO number of employees

0%about as many people as a year before

Thermo Fisher had 125,000 employees at the end of fiscal 2025, about as many as a year before.

TMO CEO pay

$79.92Mfor fiscal 2025, 92% of it in stock and options

Thermo Fisher paid its CEO $79.92M for fiscal 2025, 92% of it in stock and options.

Fragility risksCould something break it?sturdy

TMO financial health Altman Z-score

4.2Altman Z-score, safe above 3

Thermo Fisher's Altman Z-score is 4.2 (Nov 13, 2026), above 3, where the safe zone starts.

TMO quality checks Piotroski score

6 of 9checks passed

Thermo Fisher passes 6 of the 9 Piotroski checks in the 12 months to Sep 26, 2026; it misses on return on assets, long-term debt and sales for its assets.

TMO in past recessions

pretickt analysis-4%its sales in the worst one

Thermo Fisher's sales fell in 1 of the last 2 US recessions, by as much as 4% in fiscal 2009.

Price valuationIs the price reasonable?expensive

TMO price vs profit P/E ratio

36.9×a year's earnings

Thermo Fisher's P/E ratio is 36.9 (Nov 13, 2026), above its 3-year median of 32.1.

TMO price vs competitors

pretickt analysis36.9×a year's earnings, against its competitors

Investors pay 36.9 times Thermo Fisher's earnings (Nov 13, 2026), more than for Agilent (34.2), less than for Idexx Laboratories (47.8) and Danaher (38.1).

TMO analysts' target price target

+1%to their average target

Analysts' average price target for Thermo Fisher is $707, 1% above the Nov 13, 2026 close of $700.22.

TMO growth priced in fair value

pretickt analysis+14%a year, for ten years, to be worth the price

At $700.22 a share, Thermo Fisher's free cash flow must grow about 14% a year for ten years to be worth the price (Nov 13, 2026).

What is Thermo Fisher's P/E ratio?

Thermo Fisher's P/E ratio is 36.9 (Nov 13, 2026), above its 3-year median of 32.1. Investors pay 36.9 times Thermo Fisher's earnings (Nov 13, 2026), more than for Agilent (34.2), less than for Idexx Laboratories (47.8) and Danaher (38.1).

Who are Thermo Fisher's biggest competitors?

pretickt compares Thermo Fisher with Danaher, Idexx Laboratories, Agilent and Natera. Thermo Fisher's sales grew 8% in the 12 months to Sep 26, 2026, faster than Danaher (+6%), slower than Natera (+37%), Idexx Laboratories (+12%) and Agilent (+9%).

Are insiders selling Thermo Fisher stock?

Thermo Fisher's executives and directors sold a net $130M of shares in the 12 months to Nov 13, 2026; none bought.

How does Thermo Fisher make money?

Consumables brought Thermo Fisher 42% of its sales in fiscal 2025; Service 42%.

How many employees does Thermo Fisher have?

Thermo Fisher had 125,000 employees at the end of fiscal 2025, about as many as a year before.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.